Table 2.
Patients' characteristics and treatment data between standard dose group and de-escalated dose group before and after match
| Variables | Before match | After match | ||||
|---|---|---|---|---|---|---|
| De-escalated dose | Standard dose | p | Standard dose | p | ||
| Age | ≤50 | 18 (56%) | 123(53%) | 0.695 | 38(59%) | 0.770 |
| >50 | 14(44%) | 111(47%) | 26(41%) | |||
| Gender | Male | 17(53%) | 182(78%) | 0.003 | 43(67%) | 0.264 |
| Female | 15(47%) | 52(22%) | 21(33%) | |||
| T stage | T1 | 10(32%) | 51(22%) | 0.467 | 17(27%) | 0.888 |
| T2 | 11(34%) | 99(42%) | 24(37%) | |||
| T3 | 11(34%) | 84(36%) | 23(36%) | |||
| N stage | N0 | 7(22%) | 25(11%) | 0.031 | 8(12%) | 0.110 |
| N1 | 1(3%) | 39(17%) | 10(16%) | |||
| N2-3 | 24(75%) | 170(72%) | 46(72%) | |||
| chemotherapy | Yes | 25(78%) | 193(83%) | 0.548 | 54(84%) | 0.450 |
| No | 7(22%) | 41(17%) | 10(16%) | |||
| IC | Yes | 20(63%) | 143(61%) | 0.880 | 42(66%) | 0.763 |
| No | 12(37%) | 91(39%) | 22(34%) | |||